MorphoSys (MOR) Given a €98.00 Price Target by Commerzbank Analysts
MOR has been the topic of a number of other reports. Oddo Bhf set a €90.00 ($111.11) price objective on MorphoSys and gave the company a buy rating in a report on Tuesday, February 20th. JPMorgan Chase & Co. set a €97.00 ($119.75) price objective on MorphoSys and gave the company a buy rating in a report on Friday, December 29th. Berenberg Bank set a €85.00 ($104.94) price objective on MorphoSys and gave the company a buy rating in a report on Thursday, December 7th. HSBC set a €64.00 ($79.01) price objective on MorphoSys and gave the company a sell rating in a report on Friday, January 19th. Finally, Independent Research set a €93.00 ($114.81) price objective on MorphoSys and gave the company a buy rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of €84.02 ($103.73).
Shares of MorphoSys stock opened at €84.95 ($104.88) on Monday. MorphoSys has a 1 year low of €49.63 ($61.27) and a 1 year high of €88.10 ($108.77). The firm has a market capitalization of $2,490.00 and a PE ratio of -35.25.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.